Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $6 Price Target By Benzinga Newsdesk March 16, 8:14 AM RBC Capital analyst Gregory Renza reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $6 price target. NUVB
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Sector Perform on Info Servs, Maintains C$26 Price Target By Benzinga Newsdesk March 16, 8:04 AM RBC Capital analyst Paul Treiber reiterates Info Servs (TSX:ISV) with a Sector Perform and maintains C$26 price target. TSX:ISV
Read More 1 minute read Analyst Ratings News Price Target Reiteration JMP Securities Reiterates Market Outperform on Meta Platforms, Maintains $240 Price Target By Benzinga Newsdesk March 16, 8:02 AM JMP Securities analyst Andrew Boone reiterates Meta Platforms (NASDAQ:META) with a Market Outperform and maintains $240 price target. META
Read More 1 minute read Analyst Ratings News Price Target Reiteration JMP Securities Reiterates Market Outperform on Viant Technology, Maintains $6 Price Target By Benzinga Newsdesk March 16, 7:54 AM JMP Securities analyst Andrew Boone reiterates Viant Technology (NASDAQ:DSP) with a Market Outperform and maintains $6 price target. DSP
Read More 1 minute read Analyst Ratings News Price Target Reiteration JMP Securities Reiterates Market Outperform on AdTheorent Holding, Maintains $3 Price Target By Benzinga Newsdesk March 16, 7:46 AM JMP Securities analyst Andrew Boone reiterates AdTheorent Holding (NASDAQ:ADTH) with a Market Outperform and maintains $3 price target. ADTH
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on UiPath, Maintains $20 Price Target By Benzinga Newsdesk March 16, 6:38 AM Needham analyst Scott Berg reiterates UiPath (NYSE:PATH) with a Buy and maintains $20 price target. PATH
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $21 Price Target By Benzinga Newsdesk March 16, 6:24 AM HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $21 price target. KZR
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on HOOKIPA Pharma, Maintains $8 Price Target By Benzinga Newsdesk March 16, 6:21 AM HC Wainwright & Co. analyst Arthur He reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and maintains $8 price target. HOOK
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target By Benzinga Newsdesk March 16, 6:20 AM HC Wainwright & Co. analyst Andrew Fein reiterates Kamada (NASDAQ:KMDA) with a Buy and maintains $11 price target. KMDA
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target By Benzinga Newsdesk March 16, 6:17 AM HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $18 price target. CAPR